Unhealthy marketing of pharmaceutical products: An international public health concern
- 310 Downloads
I consider the current state of pharmaceutical marketing vis-à-vis ethical and legal standards and advocate measures to improve it. There is abundant evidence of unethical or illicit marketing. It fuels growing concerns about undue corporate influence over pharmaceutical research, education, and consumption. The most extensive evidence of industry transgressions comes from the United States (US), where whistle-blowers are encouraged by financial rewards to help uncover illicit marketing and fraud. Outside the US increasing evidence of transgressions exists. Recently I have observed a range of new measures to align pharmaceutical marketing practices with ethical and legal standards. In the interest of public health, I highlight the need for additional and more profound reforms to ensure that information about medicines supports quality and resource-efficient care.
Keywordspharmaceutical industry marketing promotion regulation public health
References and Notes
- Pharmaceutical Research and Manufacturers of America (PhRMA). (2008) The facts about pharmaceutical marketing and promotion, http://www.phrma.org/sites/default/files/pdf/marketing_and_promotion_facts_071108_final.pdf, accessed 23 June 2015.
- Goldacre, B. (2012) Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients. London: Fourth Estate.Google Scholar
- Braithwaite, J. (1984) Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul.Google Scholar
- US Department of Justice. (2012) GlaxoSmithKline to plead guilty and pay $3 billion to resolve fraud allegations and failure to report safety data, http://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report, accessed 23 June 2015.
- Angell, M. (2004) The Truth About the Drug Companies: How They Deceive us and What to Do About it. New York: Random House.Google Scholar
- Austad, K.E., Avorn, J., Franklin, J.M., Campbell, E.G. and Kesselheim, A.S. (2014) Association of marketing interactions with medical trainees’ knowledge about evidence-based prescribing: Results from a national survey. Journal of the American Medical Association Internal Medicine 174 (8): 1283–1290.Google Scholar
- Lundh, A., Sismondo, S., Lexchin, J., Busuioc, O.A. and Bero, L. (2012) Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 12: MR000033.Google Scholar
- US Securities and Exchange Commission (SEC). (2012) SEC charges Eli Lilly and Company with FCPA violations, http://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171487116, accessed 23 June 2015.
- US Securities and Exchange Commission (SEC). (2012) SEC charges Pfizer with FCPA violations, http://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171483696, accessed 23 June 2015.
- House of Commons Health Committee. (2005) The Influence of the Pharmaceutical Industry. London: The Stationery Office.Google Scholar
- Murphy, B. (2015) Pharmaceutical companies often violate drug advertising codes, study finds. The Pharmaceutical Journal 294 (7852).Google Scholar
- GlaxoSmithKline. (2012) GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and numerous states, http://us.gsk.com/en-us/media/press-releases/2012/glaxosmithkline-concludes-previously-announced-agreement-in-principle-to-resolve-multiple-investigations-with-us-government-and-numerous-states/, accessed 23 June 2015.
- European Medicines Agency (EMA). (2015) Handling conflicts of interests, http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/document_listing/document_listing_000178.jsp, accessed 23 June 2015.
- European Federation of Pharmaceutical Industries and Associations (EFPIA). (2014) EFPIA HCP/HCO disclosure code, http://transparency.efpia.eu/uploads/Modules/Documents/efpia-disclosure-code-2014.pdf, accessed 23 June 2015.
- International Committee of Medical Journal Editors (ICMJE). (2015) Conflicts of interest, http://www.icmje.org/conflicts-of-interest/, accessed 23 June 2015.
- Vilhelmsson, A., Davis, C. and Mulinari, S. (2016) Pharmaceutical industry off-label promotion and self-regulation: A document analysis of off-label promotion rulings by the United Kingdom prescription medicines code of practice authority 2003–2012. PLoS Medicine 13 (1): e1001945.CrossRefGoogle Scholar